Evotec (EVO) — Oversold, Undervalued, and Set Up for a Tactical Rebound
Evotec's American Depositary Shares recently traded near the 52-week low after a restructuring announcement and attendant legal noise. The business still owns a differentiated discovery and biologics services franchise, the valuation sits under $900M, and technicals show oversold conditions. This trade idea targets a bounce into the $3.40 area over…